Drug Profile
Research programme: ubiquitin ligases - Synaptic Research
Latest Information Update: 28 Sep 2020
Price :
$50
*
At a glance
- Originator Synaptic Research
- Class Antibacterials
- Mechanism of Action Botulinum toxin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Botulism
Most Recent Events
- 28 Sep 2020 No recent reports of development identified for research development in Botulism in USA
- 01 Aug 2016 Early research in Botulism in USA (unspecified route)